SynthesisDiabetes, obesity & metabolism2018

Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.

Om P Ganda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.